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The pyogenic streptococci group includes pathogenic species for humans and other
animals and has been associated with enduring morbidity and high mortality. The
main reason for the treatment failure of streptococcal infections is the increased
resistance to antibiotics. In recent years, infectious diseases caused by pyogenic
streptococci resistant to multiple antibiotics have been raising with a significant impact
to public health and veterinary industry. The rise of antibiotic-resistant streptococci
has been associated to diverse mechanisms, such as efflux pumps and modifications
of the antimicrobial target. Among streptococci, antibiotic resistance emerges from
previously sensitive populations as result of horizontal gene transfer or chromosomal
point mutations due to excessive use of antimicrobials. Streptococci strains are also
recognized as biofilm producers. The increased resistance of biofilms to antibiotics
among streptococci promote persistent infection, which comprise circa 80% of
microbial infections in humans. Therefore, to overcome drug resistance, new strategies,
including new antibacterial and antibiofilm agents, have been studied. Interestingly,
the use of systems based on nanoparticles have been applied to tackle infection
and reduce the emergence of drug resistance. Herein, we present a synopsis of
mechanisms associated to drug resistance in (pyogenic) streptococci and discuss some
innovative strategies as alternative to conventional antibiotics, such as bacteriocins,
bacteriophage, and phage lysins, and metal nanoparticles. We shall provide focused
discussion on the advantages and limitations of agents considering application, efficacy
and safety in the context of impact to the host and evolution of bacterial resistance.
Keywords: antimicrobial resistance, biofilms, pyogenic streptococci, bacteriocins, bacteriophage, nanoparticles,
nanomedicine
INTRODUCTION
The pyogenic group belonging to the genus Streptococcus includes species are habitually part of
the flora of animals (including humans) and, as such, most species are regarded as commensal,
but under fitting circumstances may cause localized and systemic infections (Nobbs et al.,
2009; Peters, 2017). Species of the pyogenic streptococci group include Streptococcus pyogenes,
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Streptococcus agalactiae, Streptococcus dysgalactiae subsp.
dysgalactiae (SDSD), and Streptococcus dysgalactiae subsp.
equisimilis (SDSE) which, together with Streptococcus
pneumoniae, are the key pathogens belonging to the genus
Streptococcus (Parks et al., 2015). For example, S. pyogenes
is the cause of numerous severe human diseases, including
septicemia and streptococcal “toxic-shock” syndrome (Isaacs
and Dobson, 2016). S. agalactiae is the most frequent cause
of sepsis and meningitis in neonates and children (Rajagopal,
2009; Melin, 2011). Considering domestic animals, S. agalactiae
is one of the main causes of bovine mastitis (Rato et al.,
2013). SDSE was primarily considered a human commensal
organism but nowadays its relevance as human pathogen is
on the raising, causing a similar range of diseases in humans
as does S. pyogenes (Brandt and Spellerberg, 2009). SDSD
has been considered an animal pathogen and is frequently
associated with bovine mastitis (Abdelsalam et al., 2013).
Human infections associated with this subspecies have
been sporadically reported (Koh et al., 2009; Park et al.,
2012; Jordal et al., 2015), and its role in human disease
remains unclear.
In recent years, severe outbreaks of infectious diseases caused
by organisms resistant to multiple antibiotics have occurred.
Drug resistance is mounting globally, threatening our capability
to treat common infections, resulting in persistent illness and
death. It is estimated that by 2050, around 10 million human
deaths per year might be attributable to antimicrobial resistance
(Neill, 2014, 2016). The increase in antimicrobial resistance is
more frightening derived from the considerable narrow number
of new antimicrobial agents currently under development (World
Health Organization, 2020). The growing of resistance in bacteria
has been associated to increased consumption of antimicrobials,
and improper prescribing of antimicrobials, leading to selective
pressure that trigger drug resistance in exposed bacteria and,
consequently, in the persistence of antibiotic resistance genes
in populations of the same ecological niches, mainly as a result
of horizontal gene transfer (Fair and Tor, 2014). Indeed, high-
throughput sequencing and other molecular genetics tools led
to a better understanding of the underlying mechanisms of
horizontal gene transfer. For instance, in average, about 20% of
the fully sequenced genome of Streptococcus consists of mobile
and exogenous DNA, comprising conjugative and composite
transposons, phage regions, and plasmid (Lier et al., 2015;
Yamada et al., 2019). Thus, horizontal gene transfer constitutes
one of the leading modes of originating gene diversity which
confers new antibiotic resistance mechanisms in Streptococcus.
These gene transfer events frequently strike in the pyogenic
group, particularly in S. pyogenes, S. agalactiae, Streptococcus
canis, SDSD, SDSE, and Streptococcus uberis (Haenni et al., 2010;
Richards et al., 2012; Wong and Yuen, 2012; Rohde and Cleary,
2016). Too, there have been reports of an increasing incidence
of multiple drug resistance (MDR) among streptococci strains,
which hamper customary empirical antimicrobial therapy for
these infections. Still, even though pyogenic streptococci remain
susceptible to most prescribed antibiotics, treatment failure due
to MDR has also been reported both in human and veterinary
patients (Doumith et al., 2017; Lai et al., 2017).
The quest for effective approaches to tackle MDR bacteria has
put forward several alternatives, such as competitive exclusion of
pathogenic bacteria via bacteriocin, and bacteriophages (Rotello
et al., 2016; Furfaro et al., 2018; Lopetuso et al., 2019). The
effectiveness of some of these new approaches for therapeutics
is highly variable, but positive effects have been reported in some
species. Irrespective of the mechanism of action, the ways bacteria
seem to be able to develop resistance to these new approaches
has not received enough attention, making it more difficult
to find long-term solutions. Herein, we present an overview
of mechanisms of resistance to antimicrobials in pyogenic
streptococci, factors that contribute to antibiotic resistance and
news approach to treating infectious diseases as an alternative to
antibiotics, such as bacteriocins, bacteriophage and phage lysins,
and nanoparticles. We shall provide focused discussion on the
advantages and limitations of agents considering application,
effectiveness, resistance development, and interactions with
the immune system.
ANTIBIOTICS AND MECHANISMS OF
RESISTANCE
An ideal antimicrobial ought to show high selective toxicity for
bacteria with minimal adverse impact to the host (Kohanski
et al., 2010). Antibacterial may be organized into four main
clusters based on the mechanism of action and target in
the bacterial cell – see summary in Table 1. Still, the
mechanisms of resistance to antimicrobials are complex, and
different mechanisms may be present in the same strain
promoting a multidrug resistance phenotype, but whose main
genotypic and phenotypic characteristics may be schematically
grouped as shown in Figure 1. Some of these fundamental
biochemical mechanisms of antimicrobial resistance include: (i)
enzymatic inactivation of antibiotics, e.g., β-lactamases (Munita
et al., 2016); (ii) modifications of the antimicrobial target
preventing efficient binding of the antibiotic, which often
results from spontaneous mutations, including genome and
RNA variations (e.g., rRNA mutations associated to resistance
to several antibiotics) (Malbruny et al., 2002; Gomez et al.,
2017); (iii) preventing drug access to targets, for example
through the reduced uptake by the cell via a decrease of
outer membrane permeability in Gram-negative and/or active
efflux pumps that increase clearance from within the cell
(Petchiappan and Chatterji, 2017).
To fully realize the propagation of antibiotic resistance, one
needs to recognize the molecular mechanisms of resistance to
antibiotics and to map the resistome in different ecological
niches. Several studies have assessed the resistome in the
environment, namely in wastewater, soil, and gut microbiota of
animals (humans included) (Pehrsson, 2016; Von Wintersdorff
et al., 2016). Metagenomics directly analyze DNA in a biological
sample, allowing for analysis of the resistome within distinct
microbial ecosystems (Von Wintersdorff et al., 2016). These
studies highlight that determinants of antibiotic resistance,
including those clinically relevant, are prevalent in these
environments (Lehtinen et al., 2019). Sequence-based studies
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TABLE 1 | Mechanisms of the main antibacterial drugs.
Mode of action Target Drug examples
Antimetabolites Folic acid synthesis
enzyme
Inhibits enzymes involved in production of
dihydrofolic acid
Sulfonamides







Interact with PBPs and inhibit transpeptidase
activity
β-lactams: penicillins (ampicillin,
amoxicillin, methicillin penicillin G,
penicillin V), cephalosporins (first,






inhibits transport of subunits across membrane Bacitracin




RNA Inhibits RNA polymerase activity Rifamycin
DNA Inhibits the activity of DNA gyrase and,







30S ribosomal subunit Promotes mismatches between codons and
anticodons, producing defective proteins that are
inserted causing disrupt the cytoplasmic membrane
Aminoglycosides: streptomycin,
gentamicin, neomycin, and kanamycin.
Inhibits the interaction of tRNAs with ribosome Tetracyclines
50S ribosomal subunit Blocks peptide bond formation among amino acids Macrolides: erythromycin and
azithromycin. Lincosamides: naturally
produced lincomycin and semisynthetic
clindamycin. Chloramphenicol.
Inhibits the formation of the initiation complex
between 50S and 30S subunits.
Oxazolidinones: including linezolid
provide large datasets, but one limitation is that they focus
on genes already known to be involved in the resistance,
or (less frequently) to predict new functions based on the
homology to known sequences. These genome annotation
schemes will provide more and more information to complement
the output of functional metagenomics, which shall result in
the identification of new determinants of antibiotic resistance
(Von Wintersdorff et al., 2016).
In general, bacterial drug resistance can be divided into
intrinsic and acquired resistance (Reygaert, 2018). Intrinsic
resistance is a naturally occurring phenomenon, which prevents
antimicrobial activity and it is common to the majority of strains
of a given species. The intrinsic resistance may be constitutive,
i.e., independent of previous antibiotic exposure (e.g., reduced
permeability of the outer membrane), or induced via the exposure
to antibiotic or environmental stress (e.g., multidrug efflux
pumps and biofilm formation) (Baldassarri et al., 2006; Cox
and Wright, 2013). Acquired resistance is due to chromosomal
point mutations or by acquisition of mobile resistance genes,
in which resistant strains emerge from previously sensitive
bacterial populations, customarily subsequently to exposure to
the antimicrobial (Haenni et al., 2010; Enault et al., 2017).
The acquisition of mobile genetic elements (MGEs), such as
bacteriophages, plasmids, integrative and conjugative elements, is
recognized as a key point in the emergence of multidrug-resistant
(MDR) strains (Lehtinen et al., 2019). The main mechanisms
of DNA uptake in bacteria are conjugation, transduction,
and transformation (Figure 2), which must be followed by
recombination to allow stable insertion into the chromosome.
These MGEs are self-transmissible elements common in
bacteria. Further to genes involved in mobility, regulation,
or maintenance, MGEs convey antibiotic resistance genes and
virulence factors, such as exotoxins (Haenni et al., 2010).
Horizontal transfer of genes (HGT) can modulate host-pathogen
interactions and extending the host range. Indeed, the use
of high-throughput sequencing tools allowed for a better
understanding of HGT. For example, in S. pyogenes the
lateral exchange of virulence genes, mediated by bacteriophage
infection, is a very important factor in the diversification of
the species. What is more, bacteriophages may convey genes
that provide for selective advantage to the host, thus fostering
their own dissemination (Colomer-Lluch et al., 2011; Von
Wintersdorff et al., 2016).
Many determinants of resistance are frequently present on a
single R plasmid (harboring several antibiotics-resistance genes),
thus, multiple resistance can be shared among bacteria in single-
event of conjugation (Nikaido, 2009). Many of these R plasmids
contain resistance genes against the main classes of antibiotics,
such as aminoglycosides, macrolides, phenicol, and tetracycline
(Nikaido, 2009).
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FIGURE 1 | General genotypic and biochemical aspects of antibiotic resistance mechanisms.
Streptococcus harbor various plasmids associated with the
transfer of antibiotic resistance and virulence (Grohmann et al.,
2003; Cook et al., 2013). In addition to plasmids, a wide variety of
transposons have been isolated in streptococci (Brenciani et al.,
2007; Fléchard and Gilot, 2014), namely Tn3-family transposons,
composite and conjugative transposons. For example, Tn916,
encoding tetM for the ribosomal protection protein TET(M),
associated to independent transfer of resistance between a
multitude of strains via a plasmid, including Enterococcus faecalis,
Staphylococcus aureus, S. pneumoniae, S. agalactiae, and SDSD
(Franke and Clewell, 1981; Haenni et al., 2010; Fléchard and
Gilot, 2014; Osei Sekyere and Mensah, 2019), that act as
reservoirs of functional antibiotic resistance genes.
Several mechanisms of antibiotic resistance among pyogenic
streptococci have been reported, whose main mechanism of
action and associated resistances shall be briefly described.
Table 2 summarizes the main antibiotics used for the treatment
of streptococcal infections and resistance mechanisms.
β-lactams, targeting the bacterial cell wall peptidoglycan,
particularly enzymes linked to peptidoglycan synthesis, are one
of the most prescribed antibiotics for streptococcal infections
due to the broad spectrum of action (Kohanski et al., 2010;
Kong et al., 2010). β-lactamases are secreted enzymes capable
of destroying these antibiotics and are the most frequent cause
of resistance, but not the only (Bush and Jacoby, 2010; Munita
et al., 2016). In fact, pyogenic streptococci have been recognized
as non-β-lactamase-producing bacteria, where resistance to
β-lactams is essentially mediated by alterations to the binding
site of penicillin-binding proteins (PBPs) (Vannice et al., 2019).
Nevertheless, a recent study based on whole-genome sequencing
revealed the presence of β-lactamases determinants of S. uberis
and SDSD isolates bovine mastitis (Vélez et al., 2017). Still, there
is a need for actional studies to assess the potential of these
β-lactamases, and the role of these species as a reservoir of
determinants of resistance.
Macrolides are the first choice against streptococcal
infections in patients allergic to β-lactam (Kanoh and
Rubin, 2010) and, clindamycin (lincosamides) has been used
for the treatment of infections associated with anaerobic
bacteria as an alternative to penicillin G (Greenwood
and Irving, 2012). Three main mechanisms have been
associated with resistance to these antibiotics: (i) target
modification by methylation of rRNA (erm genes) or target
mutations, (ii) active efflux, and (iii) enzymatic inactivation
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FIGURE 2 | Transformation is the process by which naked DNA from the external environment is incorporated into a bacterial cell. For this process is requires the
recipient cell to exhibit on its membrane special DNA binding proteins. Transduction is the process by which a phage transfers DNA from one bacterial strain to
another. Conjugation is the process mediated by cell-to-cell contact that provides direct DNA transfer. Conjugative transfer systems associated with plasmids usually
code the necessary proteins to DNA exchange. The plasmids are kept as extra-chromosomal genetic material by external selective pressure (e.g., presence of metal
or antibiotic). Overall, these mechanisms can be followed by recombination events that allow the genetic determinants to be inserted stably into the chromosome.
(Matsuzaki et al., 2005; Petinaki and Papagiannitsis, 2018).
Although most streptococci strains remain sensitive to
macrolides and lincosamides, resistance phenotypes have
emerged among pyogenic streptococci (Rato et al., 2013; Cattoir,
2016; De Greef et al., 2019).
Since active electron transport is required for aminoglycoside
uptake into bacteria, aminoglycosides have weak activity against
anaerobic bacteria (Ramirez and Tolmasky, 2010; Krause et al.,
2016). Still, low levels of resistance to aminoglycosides are
observed in most Streptococcus spp., and high-level resistance to
aminoglycosides appears to be rare. This resistance occurs due to
the production of AAC(6′)-APH(2′′), APH(3′)-IIIa, and ANT(6)-
Ia enzymes and has been demonstrated to be transferable by
conjugation (Cattoir, 2016).
Chloramphenicol-resistant streptococci are not common even
though some studies show high levels of resistance among
the pyogenic group species, namely, S. pyogenes, S. agalactiae,
and SDSE (Trieu-Cuot et al., 1993; Schwarz et al., 2004;
Woodford, 2005). Among streptococci and other Gram-positive
bacteria, the resistance to chloramphenicol is mainly mediated by
Chloramphenicol O-acetyltransferase (CAT) enzymes encoded
by plasmids or chromosomally integrated. Several CATs are
shared by streptococci, staphylococci, and enterococci strains
(Woodford, 2005).
Currently, fluoroquinolones (FQ) have also been put forward
as a therapeutic option for the treatment of streptococcal
infections (Pinho et al., 2010). However, emergence of resistance
among several streptococcal species, including SDSE, S. pyogenes,
and S. agalactiae, S. pneumoniae, and viridans group streptococci
has been reported (Guerin et al., 2000; Martinez-Garriga et al.,
2007; Duesberg et al., 2008; Pinho et al., 2010; Pires et al., 2010;
Kimura et al., 2013; Dang et al., 2014; Arias et al., 2019). The
most frequent mechanism of high-level FQ resistance is the target
modification due to mutations in parC and gyrA genes that occur
mainly in quinolone resistance-determining regions (QRDRs)
(Hooper and Jacoby, 2016; Pham et al., 2019). Resistance to FQ
can also be mediated by modifying enzymes, target-protection
proteins (Pham et al., 2019) and by increased production of
multidrug-resistance efflux pumps (Hooper, 2002).
Resistance to tetracyclines (TET) among streptococci strains
is often found in high rates (Nakamur et al., 2011; Emaneini
et al., 2014; Gherardi et al., 2014; Vélez et al., 2017; Gizachew
et al., 2019). In streptococci, genes encoding resistance to
TET are frequently acquired by MGEs, which also harbor
erythromycin resistance determinants (Brenciani et al., 2004,
2007, 2011; Emaneini et al., 2014; Cattoir, 2016). The presence of
determinants of tetracycline resistance (tet genes) in conjugative
transposons, which can efficiently translocate among related
bacteria, may explain the high prevalence of resistance (Santoro
et al., 2014). There is a significant association between tetM and
ermB (genetic determinant for erythromycin resistance) that has
been identified among the strains of pyogenic streptococci, and
it can be co-transferred among S. agalactiae and S. pyogenes
strains (Brenciani et al., 2007; Emaneini et al., 2014). There is
also evidence of the linkage between tetO and ermTR/mef A genes
(Giovanetti et al., 2003) and lysogenic transfer of these genes
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β-lactam β-lactamases via hydrolisis, e.g., BL2b;
TEM-1; TEM-47; TEM-71; TEM-89;
TEM-95
Chromosome Vélez et al., 2017
Aminoglycosides Aminoglycoside-modifying enzymes
(AMEs) – APH(3′)-IIIa; ANT(6)-Ia;
AAC(6′)-APH(2′ ′)
Chromosome and MGE, e.g., Tn4001,
Tn5405 and Tn3706 (Tn4001
derivative)
Galimand et al., 1999; Prudhomme
et al., 2002; Kristich et al., 2014;
Cattoir, 2016; Doumith et al., 2017
Chloramphenicol Chloramphenicol O-acetyltransferase
(CAT) enzyme encoded by genetic
determinants cat(pC194); cat(pC221);
cat(pSCS7); catS, and catQ
Plasmid and conjugative transposon
Tn1545 and Tn5253-like
Schwarz et al., 2004; Woodford, 2005;
Del Grosso et al., 2011; Mingoia et al.,
2015
Lincosamide LinB/A catalyze adenylylation of
antibiotics
MGE Haenni et al., 2010; Rato et al., 2013;




Tetracycline Efflux pumps Tet(K) Chromosomal insertion element Rato et al., 2013; Emaneini et al., 2014;
Nguyen et al., 2014
Quinolones Efflux pumps PmrA Chromosome Martinez-Garriga et al., 2007
Macrolides Efflux pumps Mef and Msr MGE such as Tn917 and
bacteriophage 8 m46.1.
Brenciani et al., 2004, 2007; Di Luca
et al., 2010; Del Grosso et al., 2011;
Rato et al., 2013; Hadjirin et al., 2014
Tetracycline Tet(M), Tet(O), Tet(Q), Tet(S), Tet(T),
Tet(W) ribosomal protection proteins
dissociate tetracycline from ribosome
MGE (Tn916 and Tn3701) and
bacteriophages 8 m46.1
Brenciani et al., 2004, 2007; Liu et al.,
2008; Nikaido, 2009; Di Luca et al.,
2010; Nguyen et al., 2014; Da Cunha






Point mutations primarily in quinolone
resistance-determining regions
(QRDRs), of parC and gyrA genes
Chromosome. Evidence for horizontal
transfer of QRDR between streptococci
has been reported.
Ferrándiz et al., 2000; Balsalobre et al.,
2003; Orscheln et al., 2005; Pletz et al.,
2006; Duesberg et al., 2008; Hooper
and Jacoby, 2016; Pham et al., 2019
Tetracycline;
Aminoglycosides
Modification in rRNA Chromosomal mutation Nguyen et al., 2014; Lupien et al., 2015
Macrolides Modification of 23S rRNA and/or
ribosomal proteins L4 and L22
determinants
Chromosomal mutation Malbruny et al., 2002; Jalava et al.,
2004
β-lactam Modification of penicillin-binding
proteins 1A [PBP1A], PBP2B, and
PBP2X
Chromosomal mutation Kimura et al., 2008, 2013; Pillai et al.,
2009; Fuursted et al., 2016; Moroi
et al., 2019; Vannice et al., 2019;




Modification by methylation of rRNA
(erm-class genes)
The erm(B) and erm(TR) genes are
found in the chromosome of
streptococci and conjugative
transposons, such as Tn916 family and
Tn5397 elements
Brenciani et al., 2007, 2011; Cattoir,
2016
carried by 8 m46.1 among S. pyogenes (Di Luca et al., 2010), that
contribute to a multi-resistant phenotype.
Due to the rise of pathogens resistant to multiple antibiotics,
new strategies have been proposed as an alternative to
conventional antimicrobials. One such example is the
use of as phage-derived lysins that degrade peptidoglycan
(Maciejewska et al., 2018), which may be considered as an
alternative to β-lactams, or of bacteriocins that provide a more
targeted approach, i.e., strain- or species-specific (Nigam et al.,
2014; Matsumoto-Nakano, 2018; Hols et al., 2019). Another
emerging field of research has been the use of nanoparticles,
particularly metallic nanoparticles (e.g., gold and silver), as direct
antimicrobial agents, as drug delivery systems that improve
the pharmacokinetics parameters (Masri et al., 2019a), or
taking advantage of these nanostructures’ optical properties,
e.g., photothermal ablation of cells. The potential of these new




Generally, bacteria populations may strive as planktonic, i.e.,
freely existing in solution, and/or sessile forming a biofilm.
Biofilms are defined as tri-dimensional agglomerations of cells,
attached to biotic or abiotic surfaces, and encased in a self-
produced matrix composed by extracellular polymeric substances
(Jamal et al., 2018). Their formation might be induced by
environmental changes that cause stress cells, such as nutrient
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limitation and antimicrobial agents (Garrett et al., 2008;
Kumar et al., 2017).
In humans, biofilms account for up to 80% of bacterial
infections, according to the United States National Institutes
of Health (Khatoon et al., 2018). One of the most important
characteristics of biofilms is their ability to increase bacterial
tolerance to antimicrobial agents. Biofilms protect the
microorganism not only from antimicrobial agents but
from nutrients scarcity, mechanical forces, and from the
host’s immune system. Several in vitro studies demonstrated
that bacterial biofilm could become 10 to 1,000 times more
resistant to the effects of antimicrobials as their planktonic
counterparts (Melchior et al., 2006). Therefore, biofilm
formation should be considered as a core mechanism of
resistance since it increases treatment failure and promotes
persistent infection.
Biofilm growth of streptococci has been extensively
investigated, but insights in the genetic origin and mechanisms
of biofilm formation in this genus are limited. Although
most pyogenic streptococci are able to form biofilms, there
is substantial heterogeneity among strains in the strength of
adherence to different surfaces. Like most bacterial genera,
in streptococci biofilms, a gradient of nutrients, waste, and
signaling molecules are formed, thus allowing groups of cells
to adapt to different environments within the same biofilm,
which may be growing at a different rate. Besides that, studies
show that a biofilm-specific phenotype is stimulated in a
particular subpopulation, resulting in the differential expression
of mechanisms against the antimicrobials (Konto-Ghiorghi
et al., 2009; Genteluci et al., 2015). Even though the resistance
associated to streptococci biofilms are not entirely understood,
several mechanisms have been proposed in support of increased
resistance to antimicrobials. These mechanisms result from of
the multicellular nature of biofilms, which leads to an additive (or
synergistic) effect between the biofilm community’s protection
and the conventional mechanisms of resistance referred above
(Rosini and Margarit, 2015; Young et al., 2016).
Formation of biofilms also favors horizontal gene transfer
between community members, thus provides conditions for the
uptake of resistance genes, e.g., high cell density or accumulation
of genetic elements. Some studies suggest that conjugation
is more efficient in biofilms than in planktonic cells (Van
Meervenne et al., 2014; Kragh et al., 2016). Marks et al. (2014)
demonstrated that the biofilm microenvironment of S. pyogenes
populations results in the induction of competence genes;
therefore, it is more conducive to HGT. This study shows for
the first time that S. pyogenes can be naturally transformed when
grown as biofilms.
Overall, upon biofilm formation, there is a delayed
internalization of the antimicrobial through the biofilm
matrix, as the primary physical and/or chemical diffusion
barrier prevents the entrance of polar and charged antibiotics.
Additionally, the heterogeneous growth of the biofilm cells
and activation of the stress response genes contribute to the
resistance phenotype.
The extracellular polymeric substances (EPS) matrix
composition is essential for the properties of the biofilm
since it offers cohesion and three-dimensional architecture of
biofilms (Flemming and Wingender, 2010). The EPS matrix
compose 80% of the biofilm containing alginates, poly-N-acetyl
glucosamine, extracellular teichoic acid, proteins, lipids, nucleic
acids, phospholipids, polysaccharides, and extracellular DNA.
EPS is 97% of water, which is found as a solvent, dictating
viscosity, and mobility (Flemming and Wingender, 2010; Kumar
et al., 2017; Jamal et al., 2018). For certain compounds, it is
known that the EPS matrix represents an initial barrier, but
recent studies showed that the biofilm matrix does not form an
impermeable barrier to the diffusion of antimicrobial, and other
mechanisms can contribute to promoting biofilm cell survival
(Trappetti et al., 2011).
Several reports indicate that the extracellular matrix of
pyogenic streptococcal biofilms is rich in proteins (Genteluci
et al., 2015; Young et al., 2016; Alves-Barroco et al., 2019). In
some cases, the biofilm contains a large amount of mucus-like
extracellular component, probably formed by DNA released from
dead cells (Alves-Barroco et al., 2019). A role for extracellular
DNA was also demonstrated by the reduction of biofilms formed
by SDSE isolates after treatment with DNase I (Genteluci et al.,
2015). The addition of a carbohydrate oxidant, such as sodium
metaperiodate, to the biofilm of SDSE indicated the presence
of an exopolysaccharide, like for Streptococcus mutans biofilms
(Liao et al., 2014) and Streptococcus intermedius (Nur et al.,
2013). Doern et al. (2009) examined S. pyogenes strains from
different clinical sources and demonstrated the requirement
for protein and DNA in the matrix of biofilm, and only
passive role for carbohydrates. This is in contrast to SDSE, for
which several polysaccharides have been shown to be required
(Genteluci et al., 2015).
Overall, the nature of the biofilm matrix depends on the
microbial cells, their physiological status, the nutrients available,
and the physical conditions. The composition of the EPS matrix
likely influences the resistance against different antimicrobial
classes. Responses to specific stress sources such as nutrient
limitation the bacterial cell slow its growth. During biofilm
development, a gradient is established, in which outer layers are
metabolically active and aerobic, while and the more inner layers
are anaerobic with the reduced growth rate. This slow growth
has been observed in streptococci biofilms that are frequently
accompanied to a significant increase in antibiotics resistance
(Bjarnsholt et al., 2013; Macià et al., 2014). Several antibiotics,
such as aminoglycosides, β-lactams, and fluoroquinolones, do
not seem to be active in anaerobic conditions, affecting only
the outermost layers of the biofilm (Borriello et al., 2004). Cell-
wall active antibiotics, namely, β-lactams and glycopeptide, have
minimal activity against bacteria that are not replicating and are
metabolically inactive (Del Pozo, 2018).
Clinical strains response to most antibiotics is assessed
according to standard MIC determination. However, several
studies have indicated that, as a biofilm, the same strain/isolate
may be resistant, suggesting that most of the antibiotics
evaluated would be ineffective in therapy. Still, information
regarding the minimum concentration for biofilm eradication
of pyogenic streptococcal is scarce (Conley et al., 2003;
Baldassarri et al., 2006).
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Biofilm formation of S. pyogenes protects against some drug
but does not confer complete resistance to some antibiotics,
namely, penicillin and fluoroquinolone (Conley et al., 2003;
Baldassarri et al., 2006; Young et al., 2016). Therapeutic failures
against infections caused by S. pyogenes may be due to the
ability to internalize human cell and biofilm formation facilitating
the persistence of genetically susceptible organisms, additionally
supporting the HGT, and consequently, the emergence of
virulent clones (Baldassarri et al., 2006). The increased resistance
of biofilms to antibiotics was also observed in SDSD and
S. agalactiae (Mah and O’Toole, 2001; Olson et al., 2002).
As explained above, the successful treatment of infections
caused by biofilm-forming bacteria is troubled due to the
multidrug-resistant phenotype. Conventional antimicrobial
therapy is unable to eradicate the biofilm infection.
Consequently, to fight the resistance of bacterial biofilm, several
different strategies and antibiofilm agents have been proposed.
A promising strategy is the application of nanoparticles,
which have been considered as an alternative approach to
combat and biofilm-based infections (Baptista et al., 2018).
Applications of nanomedicine and other alternative therapies
will be discussed below.
ALTERNATIVE ANTIBACTERIAL
THERAPIES
In order to tackle the growing MDR concerns, a plethora
of alternative compounds, strategies and platforms has been
proposed as an alternative to conventional antimicrobials.
Some of these alternatives are mere concepts whose promising
in vitro efficacy has been the focus of attention. Many
of these novel solutions have been proposed to be used
alone against MDR bacteria, but many other have been
proposed to be used in combinatory strategies with traditional
antibacterial drugs to enhance efficacy, circumvent the onset of
mechanisms of resistance.
Bacteriocins
Bacteriocins are peptides, of prokaryotic origin, with inhibitory
activity against diverse groups of microorganisms (Nigam et al.,
2014; Hols et al., 2019). Several authors have documented
the ability of numerous bacteriocins to inhibit the growth of
pathogenic microorganisms. Here we shall refer to a general
representation of bacteriocins as an alternative to traditional
antibiotics. Overall, bacteriocins interact with the bacterial
cell membrane and alter its properties, causing cell death.
These molecules normally only target closely related species,
and given their bactericidal or bacteriostatic effects, they
can offer an advantage relative to conventional antibiotics
since treatment could be targeted against specific pathogenic
(Lopetuso et al., 2019). These peptides are typically used by
commensals microbiota to colonize in the human gastrointestinal
tract allowing the survival of specific communities, and thus
improving gut barrier function and host immune response
(Hols et al., 2019). Four major classes of bacteriocins have been
identified: (i) Class I, including small heat-resistant peptides,
modified post-translationally, known as “lanthionine-containing
bacteriocins” (e.g., lantibiotics, sactipeptides, and glycocins); (ii)
Class II, including small heat-resistant peptides (<10 kDa)
post-translational modifications. These are “non-lanthionine-
containing bacteriocins” which are divided into four subclasses
based on their size; (iii) Class III harboring heat-labile and
large proteins (>30 kDa); and (iv) Class IV including complex
bacteriocins, namely, large proteins with carbohydrate and/or
lipid (Pieterse and Todorov, 2010; Hols et al., 2019).
Widespread applications of bacteriocins have been
documented with variable efficacy reports. There has been
some experimental evidence supporting the antimicrobial
properties of bacteriocin nisin (produced by Lactococcus) against
relevant oral pathogenic bacteria. It has been shown that nisin
A could inhibit the growth of cariogenic streptococci, including
Streptococcus gordonii, Streptococcus sanguinis, Streptococcus
sobrinus, and S. mutans (Tong et al., 2010). Additionally, it was
demonstrated that the nisin associated with poly-lysine and
sodium fluoride can inhibit the formation of S. mutans biofilms
(Tong et al., 2011).
Among bacteriocins used against bovine mastitis, besides
the nisin, the lacticin3147 has largely been researched. This
bacteriocins has proved effective against the most mastitis-
causing pathogens, namely S. aureus, SDSD, S. agalactiae and
S. uberis (Ryan et al., 1996, 1998). Studies have shown that
bacteriocins produced by several streptococci to be able to
inhibit closely related strains (Nigam et al., 2014; Matsumoto-
Nakano, 2018; Hols et al., 2019). Some S. mutans and
Streptococcus salivarius strains that are part of the commensal
microbiota of the oral cavity are also producers bacteriocin
producers (Tagg, 2004; Tagg et al., 2006). Healthy microbiota
of the nasopharynx also harbors bacteriocin-producing strains,
including S. salivarius strains. The bacteriocins produced by
this species have been investigated for the treatment of
pharyngitis and otitis (Walls et al., 2003). In order to shield
against streptococcal infections, bacteriocin-producing strains
are inoculated in the nasopharynx (Walls et al., 2003). The
ability of normal microbiota strains to inhibit the growth of
other bacteria has a critical role in its colonization of the host
and suggest that these bacteriocins provide protection against
S. pyogenes infection (Wescombe et al., 2012).
To date, few streptococci bacteriocins against mastitis-
causing pathogens have been identified. However, the natural
environment of bacteriocin-producing bacteria consists of a
particular field for application. S. uberis strains isolated from
bovine mastitis bacteriocin-producing has been described, the
most studied is the nisin U. This bacteriocin showed activity
against important mastitis-causing pathogens, specifically
E. faecalis, SDSD and S. agalactiae (Wirawan et al., 2006).
Larger bacteriocins (above 10 kDa) also produced by some
streptococci strains and are identified as bacteriolytic enzymes
or non-lytic inhibitory. Examples comprise streptococcin A-M57
produced by S. pyogenes and dysgalacticin provided by SDSE. The
genes that encode for SA-M57 (scnM57) and dysgalacticin (dysA)
have been found on plasmids pDN571 and pW2580, respectively
(Heng et al., 2006). The DysA and ScnM57 are polypeptides with
220 and 179 amino acids, respectively, both are exported via the
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Sec-dependent transport pathways. Interestingly, a pW2580-like
plasmid is also harbored by some S. pyogenes strains, emphasizing
the HGT between SDSE and S. pyogenes (Heng et al., 2006).
Overall, lateral transfer of bacteriocin production underscores the
contribution of the microbial ecology within the specific niche.
Nonetheless, the broad use of bacteriocin can also confer
threatening for its usage on a large scale. Usually, bacteriocin
resistance is acquired by lateral transfer of the immunity
gene harbored in bacteriocin-producing strain. Resistance genes
located on MGE can facilitate the transfer to closely related
or even different species providing the means to resist specific
bacteriocins (Dicks et al., 2018).
Multidrug efflux pumps also provide resistance to bacteriocins
of several bacterial species (Van Hoang et al., 2011). Furthermore,
bacteriocins may be degraded by proteolytic enzymes;
consequently, they may not be as stable as conventional
antibiotics (Tolinački et al., 2010).
Bacteriophage and Phage Lysins
Bacteriophages (or only phages) are viruses that specifically infect
bacteria. The interaction between phage and bacteria usually
involves particular receptors located in the cell membranes.
Therefore, the phage is a natural killer of bacteria (Ghosh et al.,
2019; Lopetuso et al., 2019). For this reason, the bacteriophages
and phage proteins, namely enzymes, are extensively studied as a
future alternative against bacterial infections.
There are many types of phage viruses, but the vast majority of
phages can be distinguished into lytic and temperate. The most
common approach for therapy involves lytic phages, which are
phages that induce cell lysis, and therefore cause bacterial death
(Ghosh et al., 2019), whereas the temperate phages integrate
within the host genome (lysogenic conversion) (Di Luca et al.,
2010). Typically, in the lytic phage life cycle, after the interaction
between tail fibers and the host cell surface receptors, the
phage secretes specific enzymes that degrade lipopolysaccharide,
peptidoglycan and outer membrane (in Gram-negative) to inject
the phage DNA. Subsequently, late genes are expressed and take
control of the host cell’s to then initiate phage DNA replication.
The phage DNA replicated expresses genes that encode proteins
necessary for new phage particle assembly, endolysins, and holins
for host cell lysis. Finally, the new phage particles are released into
the environment.
The most significant factor ensuring the efficacy of phage
therapy is its self-replicating nature, which distinguishes them
from conventional antibiotics. Therefore, the main advantage
of using phages for antibacterial treatment is that it can be
administered in a low dose, that is, a small number of phages
allows producing more of the particles at the infection site
(Maciejewska et al., 2018).
Since their discovery in 1915 by Frederick William Twort,
the phages were recognized as potential antibacterial, and
due to the facility of administration and absence of side
effects, phages were used immediately for antibacterial therapy
(oral and topical preparations) (Maciejewska et al., 2018). The
discovery and introduction of penicillin in the 1940s led to
the practically total abandonment of antibacterial therapy with
phage in the western countries (de Almeida and Sundberg, 2020).
However, the benefits of antibiotics were lost considerably with
the emergence and dissemination of bacterial resistance. The
emergence of infectious diseases caused by multidrug-resistant
bacterial generated an essential need for alternatives approaches
to traditional antibiotics (Chang et al., 2015; Lehtinen et al., 2019).
Along these lines, bacteriophages and phage-derived protein
therapy get revitalized.
Since the 1980s, the phage therapy revival in western
countries has been considered a possible option for combat
antimicrobial resistance (de Almeida and Sundberg, 2020). Many
research groups have concentrated on this theme of increasing
importance, with Belgium pioneering in studies for the clinical
use of phages (Pirnay et al., 2018; Jault et al., 2019). Despite the
large potential of phages for antibacterial therapy, a small number
of clinical trials have been performed in human patients. Besides
that, few clinical trials are accepted by public health authorities,
for example, the European Medicines Agency (EMA) and the
Food and Drug Administration (FDA) (Rios et al., 2016). In
the United States and European Union, the phages and phage-
encoded enzymes classified as human therapeutic material are
subjected to the same implementation regulations as traditional
antibiotics (Maciejewska et al., 2018).
There has been a growing interest in phage-derived
enzymes with antibacterial activity, including lysins (degrade
peptidoglycan), and depolymerases (that degrade polysaccharide,
e.g., capsule, biofilm matrix, and lipopolysaccharide)
(Maciejewska et al., 2018). Regarding the application of
these enzymes, previous studies, including animal models and
clinical trials, showed antibacterial activity and reaffirmed the
safety of its use (Lopetuso et al., 2019). Nonetheless, the current
legislation limits the use of recombinant enzymes in human
therapy, mainly for systemic therapy (Schmelcher et al., 2012).
The potential of phage against biofilm-forming bacteria has
been demonstrated. The ability of the bacteria to produce
biofilms has been considered the most common reason for
failure therapeutic of antibiotics due to the impermeability of
the biofilm matrix and the diversity of bacterial cells at different
metabolic stages. Studies show that some phages have naturally
depolymerases able to degrade the biofilm matrix (Abedon,
2015b). Probably, the depolymerases have evolved in response to
polysaccharide of the biofilm matrix that covers the membrane
receptor required for the interaction between the phage particle
and the host cell and the subsequent attachment. The phages
can also infect metabolically inactive bacteria of the biofilm
since the receptor is present, but the lytic cycle stays pendent
until bacterial metabolism to be active (Pearl et al., 2008). The
complete eradication by one phage is rather difficult due to a
complex structure of the mature biofilm. A combined action
(combined therapy) has been suggested as a valid approach, in
which depolymerase that degrades polysaccharides of the matrix
allowing the phage or antibiotics to achieve the bacteria (Abedon,
2015a). Phage lysins have been also effectively used to remove
bacterial biofilms (Meng et al., 2011; Shen et al., 2013; Rico-
Lastres et al., 2015).
Bacteriophages infection occurs through specific protein
receptors on the bacterial surface, which is the cause of
extreme selectivity of these agents but also their main limitation.
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Due to this high specificity, phage therapy is of narrow-
spectrum compared to traditional antibiotics whose targets are
general pathways and processes common to most bacteria (e.g.,
protein synthesis). Unlike traditional antibiotics, one particular
phage has a restricted number of strains as target, in other
words, several and different phages are required to combat
one only bacterial species. Moreover, phage-based therapy
requires the previous identification of bacteria, causing infection
to the isolation of specific lytic phage. Methods to isolate
bacteriophages with broad-host-range and modifications to
expand the specificity have been the target of several approaches,
which could reduce the number of phages needed per species
(Fairhead et al., 2017; Hyman, 2019). Moreover, the use of a
“phage-cocktail” (composed of strictly lytic phages) can expand
the spectrum of action and be administered in combination
with other antibacterial agents, thus, increasing the potential
of phage therapy.
The success of antibacterial phage-based therapy broadly
depends on the patient’s immune system (PIS) that may recognize
and inactivate viral particles. A low-level of antibodies specific
to several viral proteins can naturally exist. Moreover, during
phage therapy, the activation mechanisms of the immune
response can be triggered; thus, phage may be recognized by
the PIS, severely compromising the therapeutic effectiveness
(Borysowski et al., 2012).
The activity of antibodies in phage lysines inactivation has
also been investigated. Studies have shown that antibodies were
effective in reducing the half-life of these enzymes (Rashel et al.,
2007; Jun et al., 2014). Nonetheless, modification of lysins by
dimerization to broaden their half-life has been investigated
(Resch et al., 2011). For example, the ClyS (chimeric endolysin)
that showed insensitive to antibodies (Pastagia et al., 2011).
Furthermore, phage particles may undergo denaturation by
conformational changes irreversible or reversible. A proposed
solution is encapsulation within nanocarriers to become the
particles insoluble and protecting them from the digestive and
immune system (Balcão et al., 2014; Rios et al., 2018). Another
critical question is to get the phage particles to the infection
site, given that phages do not have pharmacokinetic properties
(Ghosh et al., 2019). One of the biggest concerns of phage-
based therapy is the gap in understanding of phage-bacteria-
human interaction, namely their safety. Concerning phage
therapy in immunocompromised patients, although considered
safe, its use may be less effective with more associated risks
(Roach et al., 2017).
Another aspect associated with security difficulties is
horizontal gene transfer. Although low, there is the possibility
of HGT affect the pathogenic potential of co-existing bacterial
strains by sharing of antibiotic resistance and virulence genes
into the population (Lim et al., 2014). The proper phage selection
against a given infection still is a challenging question. Moreover,
clinical phage resistance in vivo also is a complicated issue.
Recent studies in animal models suggest that bacterial
mutations resulting in phage-resistance may enhance the
pathogen’s fitness in its regular niche within the host (Oechslin,
2018). Experimental data showed that phage-resistance occurs
in 80% of researches targeting the intestinal environment and
50% of investigations with a model of sepsis. In human studies,
phage-resistance has also been observed.
In the pyogenic streptococcus group, strains can escape
to phage attack through several mechanisms, comprising
spontaneous mutations of the genes encoding receptor,
restriction-modification systems, abortive infection mechanisms,
and adaptive immunity mediated by CRISPR-Cas systems
(Almeida et al., 2016; Euler et al., 2016). The spontaneous
mutation is the principal mechanism emergence of resistance
and phage–bacterial coevolution. The mutations may provide
resistance by changing the bacterial surface molecules
in particular phage receptors, and that also determine
phage specificity.
Concerning modification-restriction mechanisms, it is based
on its abilities to restrict incoming foreign genetic material
and to protect host DNA from restriction through modification
(methylation, for example) of specific bases in the DNA sequence.
Due to host DNA modification, unmodified sequences are
then assumed to be foreign and thus cleaved by restriction
endonuclease (Stern and Sorek, 2011). Usually, this mechanism
causes the death of phage particles but preserves the host. If the
system fails, intruding phages will be replicated and modified by
the cell, becoming resistant to restriction. In abortive infection
(Abi), the host mechanisms arrest phage development at its
different steps, e.g., phage transcription, genome replication,
or phage genome assembly. Abi mediated resistance ultimately
results in the death of both the bacteriophage and the host.
It is a selfless defense mechanism since the host dies, but the
surrounding population is benefitted (Stern and Sorek, 2011).
Although some of these systems work similarly to toxin-antitoxin
systems, Abi systems are vastly diverse, and their modes of action
are still not completely understood.
The CRISPR-Cas system consists of a multistep process by
which small fragments of foreign nucleic acids (or protospacers)
are first recognized and included in the host genome. Afterward,
these fragments (or spacers), along with Cas proteins, are
used as an adaptive immune system that recognizes, degrades
or silences foreign nucleic acids (Bondy-Denomy et al., 2013;
Rath et al., 2015). However, phages have acquired mutation-
based strategies to evade CRISPR/Cas systems, e.g., losing their
spacer sequences or encoding products that target Cas proteins
(Stern and Sorek, 2011).
Nanoparticles
Nanomaterials have recently gained great interest due to
the variety of applications in biomedicine (McNamara and
Tofail, 2017). Nanomaterials comprise a range of constructs,
materials and functional systems of particles whose size is
between 1 and 100 nm. Particularly, these nanotechnology-
based materials have found plenty of applications as alternative
tools to traditional antibiotics and, more interestingly, as means
to prevent the surge in antibiotic resistance (Baptista et al.,
2018). The use of nanoparticles as antibiotic therapy has relied
on these nanostructures acting as carrier of drugs, either
via integration or incorporation into the nanoformulation, or
adsorbed to the surface so as to improve biodistribution and
pharmacokinetics, e.g., solubility, controlled drug liberation
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and therapeutic effectivity (Gao et al., 2018), the main
mechanism of action of metallic nanoparticles in bacteria are
described in Figure 3. However, several nanomaterials have
been proposed as antimicrobials, with particular emphasis
metallic nanoparticles (the most recent application of these
metallic nanoparticles against Streptococcus spp. are shown in
Table 3).
Some of the value of nanotechnology for antimicrobial therapy
relate to modulation of the pharmacokinetic profile, where
nanoparticle mediated drug delivery might improve conveyance
of the drug to the desired tissue. Furthermore, nanoparticles
could be designed to enhance solubility, control the release of
drug and increase clearance from the organism, thus improving
the therapeutic window of the cargo drug. Also, some synergistic
strategies may be used, such as photothermal ablation of cells,
where combination to the “traditional” chemotherapeutic may
lead to an increase of efficacy. Nevertheless, there are some
limitations to the use of these nanomaterials before their
successful translation to clinics. One is the limited amount of
data on the use of such systems to tackle infection in in vivo
models, thus preventing adequate assessment of optimal dose,
appropriate administration routes and possible interaction of
nanoparticles with cells and tissues, whose toxicological profile is
not completely understood (Baptista et al., 2018; Lee et al., 2019).
FIGURE 3 | Different mechanism of action of metallic NPs in bacteria. Nanoparticles induce wide effects in bacterial metabolism by different approaches: (i) ROS
generation: Ag, Fe, Cu, and Zn NPs induce ROS (reactive oxygen species), the ROS generated are highly reactive toward biological molecules such as proteins and
DNA and interact and damage them. (ii) Damage membrane: Ag and Cu NPs interact with chemical groups of bacterial membrane (sulfate or phosphate) and disturb
the normal functions. (iii) Drug and gene delivery systems: Au and Fe NPs could be carrier of gene moieties (DNA/RNA) that interact with bacterial gene, or deliver
drug improving some pharmacodynamic parameters. (iv) Ribosome: Au NPs inhibit the union of transfer RNA (tRNA) to ribosome. (v) Photothermal therapy of Au
NPs mediated by laser irradiation that disturb the membrane structure. (vi) Bacterial respiration: Ag NPs alter the electronic transport and inhibit the respiratory chain.





















TABLE 3 | Application of metallic nanoparticles against Streptococcus spp.
Metal Synthesis method Bacteria Highlights References
Silver Green
synthesis
Terminalia mantaly extract S. pneumoniae The biogenic Terminalia mantaly-Ag NPs showed significant
antibacterial activity compared to the respective extracts
Majoumouo et al., 2019
Allium cepa and Allium sativa extract S. pneumoniae AgNPs exhibited antibacterial activity against selected vaginal bacteria Bouqellah et al., 2019
Fruit extract of Prosopis farcta S. pneumoniae AgNPs increased the antioxidant and antibacterial activity compared
with the extract alone, due to high content in phenolic compounds.
Salari et al., 2019
Tapinoma simrothi S. pyogenes AgNPs with effective antimicrobial activity in a wide range of bacteria Sholkamy et al., 2019
Chemical
synthesis
Silver nitrate reduced by sodium
borohydrate
S. pyogenes AgNPs as carrier of new quinazolinone compounds showed enhanced
antibacterial activity
Masri et al., 2019a
Gold Green
synthesis
Justicia glauca extract S. mutans AuNPs coated with antibiotic increased efficacy against a broad range
of bacteria
Emmanuel et al., 2017
Resveratrol as a green reducing agent S. pneumoniae
S. pyogenes
AuNPs-resveratrol increased efficacy against S. pneumoniae compared
to resveratrol
Park et al., 2016
Chemical
synthesis
Reduction of gold (III) chloride
trihydrate by sodium citrate
S. pneumoniae Uptake of AuNPs by S. pneumoniae associated the antibacterial activity
to the formation of inclusion body of AuNP (IB-AuNPs), composed by
proteins, carbohydrates and lipids.




Citrate reduction of gold (III) chloride
trihydrate
S. mutans Combination of AuNPs and diode irradiation decreased CFUs Sadony and Abozaid,
2020
Gold-silver Gold-silver nanocages via galvanic replacement reaction S. mutans Au-Ag nanocages promoted the inhibition of S. mutans Wang et al., 2016
Gold-titanium Commercial TiO2 nanotubes with Au via direct current plasma sputter S. mutans Ti nanotubes sputtered with Au nanorod irradiation increased the
inhibitory effect against S. mutans
Moon et al., 2018
Green synthesis: Terminalia chebula bark extract S. pneumonia Au-TiNPs loaded with carbon nanotubes and irradiated under visible
light showed higher antimicrobial activity than ampicillin
Karthika and
Arumugam, 2017
Zinc-silver Polymeric precursor and coprecipitation S. mutans Zn-AgNPs inhibit S. mutans biofilm formation (dentistry) Dias et al., 2019
Iron Green
synthesis




FeNPs provided antimicrobial activity and antioxidant capacity
associated to compounds from extracts
Mirza et al., 2018
Chemical
synthesis
Commercial NPs S. mutans Chitosan coated FeNPs as carrier for chlorhexidine; bacteria eradication
and antibiofilm effect
Vieira et al., 2019
Ferric chloride and ferrous chloride
tetrahydrate
S. mutans FeNPs on surface for eradication of S. mutans Javanbakht et al., 2016
Solvothermy employing iron (III) chloride S. mutans Vitamin B2 coated FeNPs promoted antibacterial activity Gu et al., 2020
Copper Chemical methods: copper acetate as precursor S. mutans Hybrid Cu-chitosan NPs reduced MIC and minimum bactericidal
concentration
Covarrubias et al., 2018




Zinc Zinc acetate dihydrate as precursor S. pneumoniae ZnNPs reduced IMC and showed anti-biofilm formation activity Bhattacharyya et al.,
2018
Green synthesis: Costus igneus extract as capping and reducing agent S. mutans ZnNPs showed a dose dependent antibacterial and antibiofilm effect
against S. mutans
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Silver Nanoparticles
Traditionally, Silver (Ag) has been employed as antimicrobial,
namely silver sulfadiazine and silver nitrate (Lansdown, 2006),
which relied on the release of Ag+ that triggers a range
of processes resulting in hampered bacterial growth. Silver
nanoparticles has allowed improved release of silver ions and,
thus, enhance the bactericide action (Dakal et al., 2016). Silver
nanoparticles (AgNPs) may be synthesized by different protocols
relying on thermic vaporization, chemical or photochemical
reduction of silver ions to form nanoparticles that are then
capped either by the same reagent or by additional compounds,
which promote solubility and stability (Lee and Jun, 2019). The
most used method is based on using citrate as reducing and
capping agent of silver salts. Nowadays, other methodologies
using biological extracts (e.g., plant extracts) has been employed
for the “green synthesis” of this nanomaterial (Masooleh et al.,
2019). Regardless of the synthesis method, the antibacterial
activity of AgNPs depends on the size and shape of the particles;
for example, the antibiotic effect increases with smaller sizes
due to the dramatic increase in surface area available for ion
release and/or to interact with the bacteria. In fact, some authors
propose that AgNPs between 1 and 10 nm could interact more
efficiently with the bacteria cell membrane (Morones et al.,
2005), and spherical nanoparticles seem to be more effective
in bacterial eradication than triangles or cylinders (Raza et al.,
2016). Still, for AgNPs, size is the stronger determinant associated
with antibiotic activity, which is clear in conceptual studies
of efficiency for Pseudomonas aeruginosa and Escherichia coli
eradication (Raza et al., 2016). However, AgNPs have shown
biocidal effects against a range of bacterial species with clinical
interest, such as Staphylococcus epidermidis, Enterococcus faecalis,
Vibrio cholerae, and Salmonella spp. (Morones et al., 2005;
Sánchez-López et al., 2020).
Although the biocidal action of AgNPs has been attributed
mainly to the Ag+ release, the actual mechanism is not
yet completely elucidated. Crucial to their effect is the fact
that AgNPs tend to accumulate at the membrane where they
progressively aggregate, allowing silver ions to interact with
different functional groups, such as sulfate or phosphate, and
disturb the function of the bacterial membrane, promoting its
rupture and liberate the cytoplasmatic content (Le Ouay and
Stellacci, 2015). Other studies have suggested that Ag+ is able to
interact and inactivate some biological structures and affect the
bacteria’ respiratory process, namely inhibiting the respiratory
chain (Costa et al., 2010). However, perhaps the most widely
accepted hypothesis is the production of reactive oxygen species
(ROS), like superoxide or hydrogen peroxide, which interact with
the lipids, proteins or DNA, promoting alteration in the normal
functions, triggering lysis and cell death (Quinteros et al., 2016).
AgNPs have also found a range of industrial applications
that require some level of inhibition of bacterial growth. One
such examples is the development of new tools for odontology,
where AgNPs have been added to customary compounds for
dental implants (e.g., polydopamine and titanium) to improve
biocompatibility and provide for added antibacterial efficacy
against S. mutans, commonly implicated in the caries disease
(Choi et al., 2019). Green synthesized AgNPs by Epigallocatechin
gallate (green tea extract) as reducing and chitosan as capping
agent decreased the MIC and MBC against S. mutans (Yin et al.,
2019). What is more, these AgNPs induced lower amounts of
lactic acid and polysaccharides in the biofilm, thus enhancing
the protective action of the nanoparticle extracts. The synergistic
effect of the bio-extracts and AgNPs may be associated to
the bactericide activity of the green tea polyphenols and the
large surface area of AgNPs which increase the contact with
bacteria and facilitate disruption of cell metabolism. In addition,
E. gallate is able to inhibit the S. mutans glucosyltransferase
reducing bacterial adherence and biofilm formation. Another
interesting application for AgNPs has been its inclusion in
toothpaste formulations with promising antibacterial efficacy
against S. mutans (Ahmed et al., 2019).
Furthermore, the synergistic effect with other conventional
antibiotics makes possible the application of AgNPs as an
alternative tool to tackle MDR strains. In fact, AgNPs and
conventional antibiotics exert their biocidal action via different
mechanisms and, therefore, their combination would prevent
the development of added resistance. For example, clindamycin
has already been combined with AgNPs resulting in lower
MICs in a synergistic effect and rifampicin coupled to AgNP
increased the antibiotic effect against methicillin resistant
bacteria (Khan et al., 2019a).
Gold Nanoparticles
Gold nanoparticles (AuNPs) have also been employed in different
fields of biomedical research due to their ease of synthesis,
biocompatibility and low toxicity to higher eukaryotes. They
are easier to functionalize with different biological moieties
like DNA, mRNA, peptides, etc. than their silver counterparts.
Moreover, AuNPs present remarkable optical and photoelectric
properties that have demonstrated high potential toward the
development of new therapy tools (Amendoeira et al., 2020). The
chemical processes for the synthesis of AuNPs are similar to those
of AgNPs, where the citrate reduction method is clearly the most
used method. Still, in the last years, as for AgNPs, several green
synthesis methods with plant or other extract have been proposed
(Khan et al., 2019b).
AuNPs have been reported to exhibit antimicrobial activity
against a wide range of bacteria and fungus (Tao, 2018). Several
mechanisms of action have been highlighted as the basis of
their antimicrobial properties, namely: AuNPs may bind to
the membrane of bacteria, modify the membrane’s potential,
decrease intracellular ATP levels, disturb intracellular trafficking,
aggregate together with proteins and disturb the assembly of
tRNA to the ribosome (Cui et al., 2012). Perhaps, the main
aspect related to antimicrobial efficacy relates to nanoparticle
dispersion and the AuNPs’ surface roughness that could interact
with the bacteria membrane (Lima et al., 2013). AuNPs have also
been proposed as drug carriers, conveyors of gene therapy and
photothermal therapy (Li et al., 2019; Masri et al., 2019b).
The use of AuNPs as drug delivery systems for traditional
antibiotics has made possible to administrate drugs more
effectively and uniformly distributed toward the target tissue,
improving the efficacy and biocompatibility of antibiotic-
conjugated AuNPs. The surface of AuNPs may be easily
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functionalized with small ligands harboring carboxylic acid,
hydroxyl, or amine functional groups that can then be used
to conjugate antimicrobials (Lee et al., 2017). The so assemble
nanoformulation improves solubility of non-water-soluble drugs
and allows for controlled and localized release of the antibiotic,
for example with an external stimulus (Canaparo et al., 2019).
For example, a formulation of imipenem and meropenem on
AuNPs increased the antibacterial effect against carbapenems
resistant Gram-negative bacteria, like Klebsiella pneumoniae,
Proteus mirabilis and Acinetobacter baumannii isolated from
human patients, and decreased the MIC while potentiating the
effect in antibiotic kill test (Shaker and Shaaban, 2017). Moreover,
these studies showed a size-dependent efficacy of the drug
system, with optimal efficacy for 35 nm nanoparticles. Another
advantage antibiotic delivery system mediated by AuNPs is the
drug-controlled release, where AuNPs loaded with Amphotericin
B showed an increase of biocidal efficiency of 78%, with less
cytotoxicity and hemolytic toxicity to the host when compared
to the antibiotic alone (Kumar et al., 2019).
When AuNPs are irradiated by light with an appropriate
wavelength, they tend to convert the received energy into heat,
thus resulting in a hyperthermal effect capable to induce damage
to the membrane structure (Kirui et al., 2019; Amendoeira et al.,
2020). The antimicrobial effect through the use of photothermally
active nanomaterials may become an interesting tool against
antibiotic resistance. For example, near-infrared (NIR) radiation
is useful to promote hyperthermy based on AuNPs, effective
against S. aureus and E. coli after 10 min of irradiation at 808 nm
(Alhmoud et al., 2017). NIR photothermy using AuNPs has been
also used as an efficient technique to eliminate a broader range
of microorganism with improved antibiofilm activity. In fact this
approach was demonstrated effective at damaging the cell wall of
streptococci, such as S. mutans, S. sobrinus, Streptococcus oralis
and S. salivarius (Castillo-Martínez et al., 2015).
The combination of these two metals, Silver and Gold, in
alloy nanoparticles has also been proposed as suitable nanoagent
against microbes. In fact, such approach combines the improved
stability and ease of functionalization provided by gold, with
the higher antimicrobial activity of silver, while avoiding some
problems associated with the aggregation and toxicity to the
host (Dos Santos et al., 2012). The positive results of this
association have been proposed in a system where gold-silver
alloy “nanoflowers” decreased the MIC against E. coli three-
fold when compared to AgNP alone (Yan et al., 2018). Gold-
silver alloy nanoparticles have shown their potential to eradicate
biofilm and reduce the MICs against Gram-positive and Gram-
negative bacteria, which could then be used to circumvent
drug resistance (Ramasamy et al., 2016). Kyaw et al. (2017)
showed that submitting triangular AuNPs coated by silver to laser
irradiation, induced a change of shape to spherical and increased
the antibacterial activity.
Other Metallic Nanoparticles
Nanoparticles employing iron (Fe) have been applied due to
their antimicrobial properties, which has been associated with
the generation of ROS (Arakha et al., 2015). The most used is
iron oxide nanoparticles which provide good efficiency in a wide
range spectrum mediated by the damage in different structures
like proteins or DNA (Saqib et al., 2019). Most of these iron
nanoparticles present some magnetic properties that may be
used for a range of applications, from diagnostics to therapeutics
(Rodrigues et al., 2019). Magnetic nanoparticles have been shown
to interfere with the thiol groups at the respiratory base of
bacteria and, thus, assisting in disrupting effective metabolism,
resulting in biocidal activity against some drug resistant bacteria
(Madubuonu et al., 2019). Ion NPs have also been used as delivery
vehicles for antibiotics, such as chlorhexidine and erythromycin
against S. mutans (Vieira et al., 2019).
Copper nanoparticles have also been used as antimicrobial
against a wide range of microorganisms including bacteria,
fungi, and even algae (Hou et al., 2018; Sardella et al.,
2018). As for AgNPs, the size is related to CuNP activity
due to the dramatic increase of the surface/volume ratio,
which promote the generation of ROS that trigger cell damage
according, such as oxidation of proteins, cleavage of DNA/RNA
molecules or lipid peroxidation in membranes (Shaikh et al.,
2019). Usually, CuNPs are combined within polymers or
functionalized in core-shell structures to provide stability and
control possible ion leakage (Anyaogu et al., 2008). For example,
CuNPs coated with chitosan showed an antibacterial effect
comparable to that of traditional oral antimicrobial agents
(chlorhexidine and cetylpyridinium chloride) against S. mutans
(Covarrubias et al., 2018). In another example, the combination
of AgNPs and CuNPs was shown to have a preventive
and therapeutic effect in mastitis caused by S. agalactiae
(Kalińska et al., 2019).
Some authors have studied the antibacterial activity of zinc
NPs (ZnNPs) against Streptococcus mitis, where the biocidal
action was associated to ROS induction identified via the
increase of superoxide dismutase activity (SOD) (Khan et al.,
2016). Moreover, ZnNPs showed the capability to inhibit the
formation of biofilm by S. mitis in a dose dependent manner,
corroborated the evaluation of bapA1 gene expression, which is
associated to generation of the biofilm. In another study, ZnNPs
showed the capability to inhibit S. sobrinus biofilm formation
(Aydin Sevinç and Hanley, 2010).
CONCLUDING REMARKS
The progressive emergence of resistance to conventional
antibiotics is reducing the ability to control infectious diseases
and, particularly, those caused by pyogenic streptococci. To
combat this public health threat, several alternative strategies
have been proposed, and the promising efficacy in vitro of some
of these antibacterial approaches has been the focus of attention.
Despite the progress achieved to date, most alternative
approaches are of narrow spectrum unlike the broad-spectrum
of conventional antibiotics. However, the combined action of
one of these alternative approaches with traditional antibiotics
may increase the success rate of therapeutics once that most new
strategies attenuate bacterial pathogenesis allowing bacteria to
be eliminated by antibiotics and action of the immune system.
Moreover, combination therapies may decrease the selective
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pressure for resistance to antibiotics, and consequently to reduce
the rate of emergence of resistance.
Bacteriocins are considered as a hopeful therapeutic
alternative caused by its proven efficacy and chemical structural
and functional diversity. Nonetheless, the broad use of
bacteriocin can also confer threatening for its usage on a large
scale, namely, the possible resistance to bacteriocins could
limit their future way. Bacteriophages allow the development
of specific therapies, phage-derived enzymes can be used as
a substitute for conventional antibiotics, for example, phage-
derived lysins that degrade peptidoglycan can be considered as
an alternative to β-lactam antibiotics. However, the advancement
of new laws that regulate the use of Bacteriophages and phage-
derived enzymes is necessary. The application of nanomaterials
may provide for new therapy tools to assist in tackling the
traditional mechanisms of resistance. Still, there is plenty of
work ahead to facilitate the translation to the clinics, namely
toward better characterization of these materials, the capability
to effectively scale-up for widespread use, and clarification
of toxicity aspect, which altogether pave the way for robust
assessment in clinical trials. Nowadays, the cost associated
with the development of nanotechnology platforms is high
and, consequently, the use of more conventional therapies are
still preferred.
The most significant concern safety of alternative therapies
is the gap of understanding of interaction with the human
host. Thus, evaluate the impacts of alternative therapies on
the host is essential for future widespread application. Future
studies must investigate in vivo efficacy of combination therapy
to assess their potential, impact of the host, and evolution of
bacterial resistance.
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